Halia Therapeutics Announces Positive Phase 2a Data for Ofirnoflast in Lower-Risk MDS at ASH 2025
Tremonton
Archived
•
December 8, 2025
•
– New findings demonstrate a 72% HI-E response rate at Week 16 with meaningful hemoglobin improvement –
Source: https://www.tremontonleader.com/search/?f=rss&t=article&l=50&c=news* - Read Original
"Free Quote Today"
Discussion (0)
Please log in to post a comment.
No comments yet. Be the first to share your thoughts!
Sponsored
"What you put in is not always what you get out."